Raily Aesthetic Medicine International Holdings Limited (“Raily Aesmed”) has issued a circular convening its 2026 annual general meeting for 26 June 2026 in Hangzhou.

Key agenda items • 2025 Financials: Shareholders will be asked to adopt the audited consolidated statements for the year ended 31 December 2025 together with the directors’ and Ernst & Young’s reports. • Board changes: Independent non-executive directors Dr Lin Hai, Ms Yang Xiaofen and Mr Liu Teng stand for re-election. • Auditor re-appointment: Ernst & Young is nominated for another term; the audit fee for FY-2026 is estimated at RMB2.20 million. • Share mandates: – Issue mandate up to 20 % of issued share capital (about 111.42 million shares based on 557.08 million shares in issue). – Repurchase mandate up to 10 % (about 55.71 million shares). – Extension to increase the issue mandate by the number of shares repurchased. • Share option scheme revamp: – Amendments align the plan with Chapter 17 of the Listing Rules, introduce a minimum 12-month vesting period (with limited exceptions) and allow claw-back provisions. – Scheme Mandate Limit set at 10 % of issued shares (approximately 55.71 million shares). – A separate Service Provider Sublimit capped at 1 % (about 5.57 million shares). – Outstanding options total 47.28 million. • Constitutional update: Adoption of a third amended and restated memorandum and articles to incorporate the Hong Kong uncertificated securities market regime and other housekeeping refinements.

Administrative details • Register of members closes 23–26 June 2026; record date is 26 June 2026. • Proxy forms must reach Tricor Investor Services by 24 June 2026, 3:00 p.m. Hong Kong time, or be submitted electronically via the designated website.